希玛眼科香港上市 腾讯背景获青睐

希玛眼科香港上市 腾讯背景获青睐

1 月28 日

香港眼科诊所希玛眼科C-MER EYE CARE Holdings（3309）于香港联合交易所上市，并于1 月15 日开始交易，共发行发行1.97 亿股，筹集约5.7 亿港元。

1 月15 日，C-MER 的股价收于5.11 港元，较招股价2.90 港元上涨76.21％。

C-MER 认购人数为1500 倍，超过同为有腾讯背景的阅文集团，打破香港股市11 年以来的记录。

该公司吸引了众多大牌基石投资者，包括腾讯，华立和冈瑟集团，三家通过IPO 共投资1.87 亿港元。

C-MER 计划将43%IPO 所得的收益用于收购三家中国眼科医院，并投资40%于大陆新建三家医院。

招商证券（香港）是首次公开招股的唯一发起人。

Shares of C-MER Eye Care surge in Hong Kong after got its IPO

Hong Kong based eye clinic C-MER EYE CARE Holdings（3309）has listed on the Stock Exchange of Hong Kong and started trading on January 15, issuing 197 million shares and raising about HK$570 million.

C-MER’s shares closed at HK$ 5.11 on January 15, increasing 76.21% from its offer price of HK$2.90.

Its shares were oversubscribed more than 1,500 times, hotter than the Tencent-backed China Literature and breaking the 11-years’ record in Hong Kong.

The company has attracted many big-name cornerstone investors, including Tencent, Wah Li and Gunther Group, with the three investing a total of HK$187.2 million through the IPO.

C-MER plans to spend about 43 percent of the IPO proceeds on the possible acquisition of three Chinese eye hospitals and 40percent on launching three hospitals on the mainland.

China Merchants Securities (HK) is the sole sponsor of the IPO.